{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:56Z","timestamp":1791486836707,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116718","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:51:24Z","timestamp":1715601084000},"page":"116718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Bispecific T cell engager-armed T cells targeting integrin \u03b1\u03bd\u03b26 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma"],"prefix":"10.1016","volume":"175","author":[{"given":"Kwanpirom","family":"Suwanchiwasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermchai","family":"Somboonpatarakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornpimon","family":"Yuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-8031","authenticated-orcid":false,"given":"Jatuporn","family":"Sujjitjoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-1967","authenticated-orcid":false,"given":"Piriya","family":"Luangwattananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8275-8488","authenticated-orcid":false,"given":"John","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa\u2011thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-3000","authenticated-orcid":false,"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116718_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/IJGM.S186854","article-title":"Cholangiocarcinoma: a guide for the nonspecialist","volume":"12","author":"Alsaleh","year":"2018","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.biopha.2024.116718_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2016.11.012","article-title":"Cholangiocarcinoma","volume":"116","author":"Squadroni","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.hpb.2017.08.025","article-title":"The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma","volume":"20","author":"van Vugt","year":"2018","journal-title":"HPB (Oxf. )"},{"issue":"4","key":"10.1016\/j.biopha.2024.116718_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3892\/mco.2021.2234","article-title":"Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: a case report","volume":"14","author":"Sota","year":"2021","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2010.10.009","article-title":"Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer","volume":"80","author":"Furuse","year":"2011","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116718_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071569","article-title":"Immunotherapy in advanced biliary tract cancers","volume":"13","author":"Boil\u00e8ve","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biopha.2024.116718_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116718_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"22","key":"10.1016\/j.biopha.2024.116718_bib10","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.biopha.2024.116718_bib11","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.biopha.2024.116718_bib12","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/bmt.2013.133","article-title":"Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study","volume":"49","author":"Lum","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bbmt.2015.12.030","article-title":"Targeting CD138-\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable antimyeloma immunity.","volume":"22","author":"Lum","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002194","article-title":"Phase II clinical trial using anti-CD3 \u00d7 anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer","volume":"9","author":"Lum","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1078-0432.CCR-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x Anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000176","article-title":"Activated T cells armed with bispecific antibodies kill tumor targets","volume":"22","author":"Bhutani","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2024.116718_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2407-13-83","article-title":"Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies","volume":"13","author":"Zitron","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.116718_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.biocel.2018.04.013","article-title":"Integrin \u03b1v\u03b26: structure, function and role in health and disease","volume":"99","author":"Koivisto","year":"2018","journal-title":"Int J. Biochem Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.2168","article-title":"Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival","volume":"212","author":"Hazelbag","year":"2007","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116718_bib21","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/0008-5472.CAN-07-0245","article-title":"A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer","volume":"67","author":"Elayadi","year":"2007","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2024.116718_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju169","article-title":"Therapeutic targeting of integrin \u03b1v\u03b26 in breast cancer","volume":"106","author":"Moore","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.biopha.2024.116718_bib23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1177\/002215540205001010","article-title":"Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer","volume":"50","author":"Ahmed","year":"2002","journal-title":"J. Histochem Cytochem"},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2559.2004.01919.x","article-title":"Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro","volume":"45","author":"Sipos","year":"2004","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.biopha.2024.116718_bib25","article-title":"Integrin \u03b1v\u03b26 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol. Res Pr."},{"issue":"7","key":"10.1016\/j.biopha.2024.116718_bib26","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.7150\/thno.38702","article-title":"Integrin \u03b1v\u03b26-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus","volume":"10","author":"Moore","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2024.116718_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2017.04.025","article-title":"Investigating in vitro and in vivo \u03b1v\u03b26 integrin receptor-targeting liposomal alendronate for combinatory \u03b3\u03b4 T cell immunotherapy","volume":"256","author":"Hodgins","year":"2017","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2745","article-title":"High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6","volume":"222","author":"Saha","year":"2010","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymthe.2016.10.012","article-title":"Targeting of aberrant \u03b1v\u03b26 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells","volume":"25","author":"Whilding","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2024.116718_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and Co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2024.116718_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11095-018-2436-z","article-title":"Chimeric antigen receptor T-cells (CAR T-Cells) for cancer immunotherapy - moving target for industry?","volume":"35","author":"Salmikangas","year":"2018","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.TP.0000110292.73873.25","article-title":"Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT","volume":"77","author":"Maruyama","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13577-020-00334-w","article-title":"Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient","volume":"33","author":"Sripa","year":"2020","journal-title":"Hum. Cell"},{"issue":"13","key":"10.1016\/j.biopha.2024.116718_bib35","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1074\/jbc.M610461200","article-title":"Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands","volume":"282","author":"DiCara","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2009.12.006","article-title":"The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma","volume":"52","author":"Patsenker","year":"2010","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116718_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041004","article-title":"\u03b24 and \u03b26 integrin expression is associated with the subclassification and clinicopathological features of intrahepatic cholangiocarcinoma","volume":"19","author":"Soejima","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116718_bib38","first-page":"910","article-title":"2D and 3D cell cultures - a comparison of different types of cancer cell cultures","volume":"14","author":"Kapa\u0142czy\u0144ska","year":"2018","journal-title":"Arch. Med. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs--past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol. Rev."},{"issue":"5891","key":"10.1016\/j.biopha.2024.116718_bib41","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12864-021-07435-2","article-title":"Blinatumomab-induced T cell activation at single cell transcriptome resolution","volume":"22","author":"Huo","year":"2021","journal-title":"BMC Genom."},{"key":"10.1016\/j.biopha.2024.116718_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00624","article-title":"Regulation of T helper cell fate by TCR signal strength","volume":"11","author":"Bhattacharyya","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116718_bib44","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.4049\/jimmunol.0900646","article-title":"CD69 controls the pathogenesis of allergic airway inflammation1","volume":"183","author":"Miki-Hosokawa","year":"2009","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065494","article-title":"Crucial role for CD69 in the pathogenesis of dextran sulphate sodium-induced colitis","volume":"8","author":"Hasegawa","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf9154","article-title":"Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation","volume":"1","author":"Hayashizaki","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2024.116718_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2 \u2013 IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010132","article-title":"Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy","volume":"15","author":"Carrasco-Padilla","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.biopha.2024.116718_bib49","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-14-2280","article-title":"Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial","volume":"21","author":"Lum","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061650","article-title":"Role and potential of different T helper cell subsets in adoptive cell therapy","volume":"15","author":"Andreu-Sanz","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20101876","article-title":"Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer","volume":"208","author":"De Monte","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.biopha.2024.116718_bib52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jso.21725","article-title":"Evaluations of interferon-\u03b3\/interleukin-4 ratio and neutrophil\/lymphocyte ratio as prognostic indicators in gastric cancer patients.","volume":"102","author":"Ubukata","year":"2010","journal-title":"J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib53","first-page":"1153","article-title":"Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer","volume":"13","author":"Kusuda","year":"2005","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib54","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.4049\/jimmunol.167.5.2972","article-title":"Predominant Th2\/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer","volume":"167","author":"Sheu","year":"2001","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib55","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1078-0432.CCR-08-1980","article-title":"Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma","volume":"15","author":"Nevala","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib56","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2024.116718_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1192303","article-title":"The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment","volume":"14","author":"Pan","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.116718_bib59","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2024.116718_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/285193","article-title":"Phase I study of anti-CD3 x Anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients","volume":"2015","author":"Vaishampayan","year":"2015","journal-title":"Prostate Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003771","article-title":"Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies","volume":"10","author":"Park","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib64","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib65","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41598-021-85747-9","article-title":"Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma","volume":"11","author":"Supimon","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2024.116718_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265773","article-title":"Antitumor activity of T cells secreting \u03b1CD133-\u03b1CD3 bispecific T-cell engager against cholangiocarcinoma","volume":"17","author":"Sangsuwannukul","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2024.116718_bib67","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2024.116718_bib68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2024.116718_bib69","first-page":"1671","article-title":"Programmed Death-Ligand 1 (PD-L1) expression associated with a high neutrophil\/lymphocyte ratio in cholangiocarcinoma","volume":"18","author":"Sangkhamanon","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224006024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:41:15Z","timestamp":1741030875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224006024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":69,"alternative-id":["S0753332224006024"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116718","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific T cell engager-armed T cells targeting integrin \u03b1\u03bd\u03b26 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116718"}}